British Journal of Medical & Surgical Urology
Volume 2, Issue 3 , Pages 92-99 , May 2009

Modern chemotherapy strategies for management of ‘Hormone Resistant Prostate Cancer’ (HRPC)—When should the urologist refer?

  • Raj A. Persad

      Affiliations

    • Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HW, United Kingdom
    • Corresponding Author InformationCorresponding author at: UHBristol NHSFT, United Kingdom.
    • ,
  • Amit Bahl

      Affiliations

    • Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8HW, United Kingdom

Received 15 November 2008 ,Accepted 14 December 2008.

References 

  1. Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD005247. DOI:10.1002/14651858.CD005247.pub2.
  2. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. JCO Early Release, published online ahead of print Jul 21 2008. J Clin Oncol, 10.1200/JCO.2007.15.9749.
  3. Armstrong AJ, George DJ. Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. Ther Clin Risk Manag. 2007;3:877–883
  4. Dawson NA. Epothilones in prostate cancer: review of clinical experience. Ann Oncol. 2007;18(Suppl 5):v22-7
  5. Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother. 2008;42:91–98
  6. Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2007;7:1893–1902
  7. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:1810–1815
  8. Cancer Research UK. UK prostate cancer incidence statistics (http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence; accessed 11 August 2008).
  9. National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment. National Institute for Clinical Health and Excellence full guideline. February 2008 (www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf; accessed 11 August 2008).
  10. National Institute for Clinical Excellence. Improving outcomes in urological cancers. The manual. Guidance on Cancer Services. September 2002.
  11. National Institute for Clinical Health and Excellence. Docetaxel for the treatment of metastatic hormone-refractory prostate cancer. Technology Appraisal 101. June 2006 (www.nice.org.uk/nicemedia/pdf/TA101guidance.pdf; accessed 11 August 2008).
  12. Oh WK, Tully P, Kantoff PW, Regan MM. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate cancer. Cancer. 2003;97:2171–2179
  13. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71(3 Suppl):1098–1109
  14. Tannock IF, de Wit R, Berry WR, Horty J, Pluzanska A, Chi AM, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
  15. Eymard JC, Priou F, Zannetti A, Ravaud A, Lepillé D, Kerbrat P, et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol. 2007;18:1064–1070
  16. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
  17. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25:669–674
  18. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532–2539
  19. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242–245
  20. National Institute for Clinical Excellence. Improving supportive and palliative care for adults with cancer. The Manual. March 2004.
  21. National Cancer Peer Review Programme 2004–2007. National Report. June 2008. National Cancer Action Team (www.cquins.nhs.uk/download.php?d=CancerAnnualRv2.pdf).
  22. Prostate Charter for Action. Because men matter. November 2007 (www.prostatecharter.org.uk/lib/docs/because%20men%20matter%20-%20the%20case%20for%20clinical%20nurse%20specialists%20in%20prostate%20cancer.pdf).
  23. Richards M. Cancer 2012 Visions. Department of Health. December 2007 (www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_080975?IdcService=GET_FILE&dID=155390&Rendition=Web).
  24. Prostate cancer visions 2012. Department of Health. December 2007 (www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_080975?IdcService=GET_FILE&dID=155384&Rendition=Web).
  25. Echlin KN, Rees CE. Information needs and information-seeking behaviors of men with prostate cancer and their partners: a review of the literature. Cancer Nurs. 2002;25:35–41
  26. National Institute for Health and Clinical Excellence. Understanding NICE guidance. Prostate cancer. February 2008.

PII: S1875-9742(08)00153-5

doi: 10.1016/j.bjmsu.2008.12.009

British Journal of Medical & Surgical Urology
Volume 2, Issue 3 , Pages 92-99 , May 2009

Article Tools

* Image Usage & Resolution